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Highlights 
• Provisional tolerable intake value was derived for intravenous exposure to 
nanoparticles released from medical devices. 
• Critical study selection was based on the Annapolis Accords principles and 
Toxicological Data Reliability Assessment Tool. 
• Modifying factor of 1,000 was determined by scientific review and analysis accounting 
for uncertainties. 
• Provisional tolerable intake for i. v. exposure to silver nanoparticles was calculated to 
be 0.14 µg/kg bw/day. 
• Methodology presented is appropriate for deriving provisional tolerable intake value for 
nanoparticles in general. 
Abstract 
Silver nanoparticles (AgNP) are incorporated into medical devices for their anti-microbial 
characteristics. The potential exposure and toxicity of AgNPs is unknown due to varying 
physicochemical particle properties and lack of toxicological data. The aim of this safety 
assessment is to derive a provisional tolerable intake (pTI) value for AgNPs released from 
blood-contacting medical devices. A literature review of in vivo studies investigating critical 
health effects induced from intravenous (i. v.) exposure to AgNPs was evaluated by the 
Annapolis Accords principles and Toxicological Data Reliability Assessment Tool (ToxRTool). 
The point of departure (POD) was based on an i. v. 28-day repeated AgNP (20 nm) dose 
toxicity study reporting an increase in relative spleen weight in rats with a 5% lower confidence 
bound of the benchmark dose (BMDL05) of 0.14 mg/kg bw/day. The POD was extrapolated to 
humans by a modifying factor of 1,000 to account for intraspecies variability, interspecies 
differences and lack of long-term toxicity data. The pTI for long-term i. v. exposure to 20 nm 
AgNPs released from blood-contacting medical devices was 0.14 μg/kg bw/day. This pTI may 
not be appropriate for nanoparticles of other physicochemical properties or routes of 
administration. The methodology is appropriate for deriving pTIs for nanoparticles in general. 
Keywords 
Silver nanoparticles, Safety assessment, Provisional tolerable intake, Medical devices, Intravenous, Uncertainty 
factors, Point of departure, Annapolis accords, ToxRTool 
1. Introduction 
Nanotechnology has many applications in medical devices; however, knowledge gaps exist inhibiting 
assessment of the risk of exposure and toxicity of nanoparticles released from medical devices to 
patients (Wijnhoven et al., 2009). Prediction of the toxic effects of nanoparticles could be calculated 
from the known toxicity of their bulk materials but is prevented due to fundamental physical and 
chemical properties that change as the particle size is decreased within the nanoscale range (Lai and 
Sayre, 2009, SCENIHR, 2009). Safety assessment of nanoparticles is further complicated by the vast 
number and variety of physicochemical properties produced differing widely by particle size, shape, 
agglomeration state, crystal structure, chemical composition, surface area and surface properties (Pang 
et al., 2016, Lai and Sayre, 2009, Warheit et al., 2007, Isakovic et al., 2006, Sayes et al., 2006a, Sayes 
et al., 2006b, Nemmar et al., 2003). A stringent battery of biological tests for each nanomaterial with 
varying physicochemical particle properties on a case-by-case basis would be costly, time-consuming 
and impractical (Lai, 2015, Oberdorster et al., 2005). 
To address this complex problem, provisional tolerable intake (pTI) values can be determined for 
exposure to nanoparticles of specific physicochemical properties, routes of entry and durations of 
exposure. A pTI value is a dose estimate of the average daily intake of a chemical over a period of time 
based on body mass and is considered to be without appreciable harm to human health 
(ANSI/AAMI/ISO 10993-17:2002/(R)2012, 2003). A pTI is normally expressed in milligrams per 
kilogram of body mass per day (mg/kg bw/day) and derived as a part of establishment of an allowable 
limit for a leachable chemical in a medical device. 
Silver nanoparticles (AgNPs) are incorporated into blood-contacting medical devices for their anti-
microbial properties, such as in intravascular (i. v.) catheters (Wijnhoven et al., 2009). The toxic effects 
induced by AgNPs have been evaluated using in vitro and short-term in vivo studies (Dubey et al., 2015, 
Gaillet and Rouanet, 2015, Ge et al., 2014, Wijnhoven et al., 2009); however, the potential exposure and 
subsequent toxicity of AgNPs released from medical devices via i. v. exposure to patients is not 
completely understood. The aim of this safety assessment is to derive a pTI value for AgNPs released 
from blood-contacting medical devices. A comprehensive literature review of in vivo studies 
investigating critical health effects induced from i. v. exposure to AgNPs was reviewed 
(ANSI/AAMI/ISO 10993-17:2002/(R)2012, 2003) and evaluated by the Annapolis Accords principles 
as described by Gray et al. (2008). Key studies were further analyzed by the Toxicological Data 
Reliability Assessment Tool (ToxRTool) (Schneider et al., 2009) to determine the critical study for use 
in derivation of the pTI. 
The point of departure (POD) is the most sensitive critical health effect reported in the critical study 
typically presented as a no-adverse-effect-level (NOAEL) or bench mark dose (BMD) value (FDA, 
2015). The POD is then extrapolated to humans by a modifying factor (MF) determined based on 
scientific review and analysis to account for uncertainties including intraspecies variability, interspecies 
differences and lack of long-term toxicity data. The derivation of a pTI dose is similar to the 
methodology used in the safety assessment of di(2-ethylhexyl)phthalate (DEHP) (FDA, 2001) released 
from PVC medical devices and in Weldon et al. (2016) in the development of an occupational exposure 
limit for silver nanoparticles. The pTI derived in this work should be considered provisional because a 
limited number of critical toxicological studies are currently available and may not be appropriate for 
nanoparticles of other physicochemical properties or routes of AgNP administration. The methodology 
used was deemed appropriate for deriving pTIs for nanoparticles in general. 
2. Literature review and selection of toxicological studies 
2.1. Criteria for selection of toxicological studies 
A comprehensive literature search using PubMed, Web of Science and Embase was conducted to 
identify in vivo studies investigated the critical health effects after i. v. exposure to AgNP that were 
published from August 31, 2006 to August 31, 2016. Studies were evaluated based on principles 
outlined in the Annapolis Accords on The Use of Toxicology in Risk Assessment and Decision-Making 
(Gray et al., 2008) and are presented in Table 1. Criteria for inclusion or exclusion of a study included: 
1) administration route similar to the route of exposure to medical devices containing AgNPs, 2) 
relevance of the toxicological effects to human health, 3) clearly established critical health effects 
between a biomarker and functional endpoint, so that only studies with effects broadly considered to be 
adverse (histopathological or functional changes) would be used for pTI derivation; and 4) high quality 
of the published data based on rigor, power, corroboration, universality, proximity, relevance and 
cohesion (Gray et al., 2008). 
Table 1. Criteria for selection of toxicological studies based on Annapolis Accords principles.a 
Principle Criteria for Inclusion in Derivation of a Provisional Tolerable Intake Value 
Rigor 
− Evaluated for proper conduct and analysis. 
− Greater weight given to more rigorous studies. 
− Studies with poor methods discounted. 
Power 
− Statistical power of the experimental design examined for ability to detect effects of a given 
magnitude. 
− For example, some "negative” studies may misinterpret a low level of response as a lack of 
response. 
Corroboration 
− Determine if effects are replicated in similar studies or under varied conditions to predict if 
effects would be seen under conditions of human exposure as well. 
− Conversely, lack of corroboration of effects provides a basis for doubting either the validity of 
single experimental results or their applicability to other species or conditions of exposure. 
Universality − Effect seen in multiple species by various routes of exposure gives confidence that the effect may apply to humans. 
Principle Criteria for Inclusion in Derivation of a Provisional Tolerable Intake Value 
− If an effect is restricted to a certain species, strain, or route of administration, there is less 
confidence in the ability to generalize the response to other species or routes. 
Proximity 
− When effects exist in a species taxonomically-related to humans or at exposure doses similar 
to those expected in humans, such results weigh more heavily than effects found in 
taxonomically less related species by less relevant routes or at markedly different doses. 
Relevance 
− Knowledge of the underlying biologic basis for toxicity in animals can assist in determining 
whether similar metabolism, mechanisms of damage and repair and molecular targets of toxic 
action occur in humans. Accordingly, confidence in applicability to humans can increase or 
decrease. 
Cohesion 
− Extent to which all data are consistent and subject to a single, biologically plausible 
explanation increases the weight-of-evidence when comparing situations where inconsistencies 
require ad hoc explanations and exceptions to general patterns. 
aPrinciples outlined as in (Gray et al., 2008). 
Studies that met the Annapolis Accords principles were furthered analyzed by the ToxRTool. The 
ToxRTool was developed by the European Commission's Joint Research Center in 2009 (Schneider 
et al., 2009) and built upon Klimisch categories (Klimisch et al., 1997) to evaluate peer-reviewed 
publications providing criteria and guidance for accessing the reliability of toxicological studies. The 
methodology of how the tool assesses data reliability from a toxicological study is previously described 
in Schneider et al. (2009). For our use, the in vivo spreadsheet of the ToxRTool was used to determine if 
21 criteria were met in the following 5 areas: (1) test substance identification, (2) test organism 
characterization, (3) study design description, (4) study results documentation and (5) plausibility of 
study design and data. To minimize rater bias during analysis and provide a more objective screening 
(Segal et al., 2015), three raters were employed to score each study independently while blinded to the 
other's ratings. Ratings were jointly reviewed to conclude the score of the study. Studies that are 
categorized as reliable (scores of 1 or 2) are deemed appropriate for use in derivation of the pTI. 
2.2. Summarization of in-vivo toxicological data 
The comprehensive literature review identified eighteen (18) in vivo studies investigating the critical 
health effects after i. v. AgNP exposure. These studies are summarized in Table 2 and in more detail in 
the Supplemental Material considering study methodology including animal model used, 
characterization of AgNPs employed, AgNP treatment dose, exposure and duration, toxicological health 
effects seen, POD reported and appropriateness of the study for derivation of the pTI based on the 
Annapolis Accords. A study assessed to be lacking in any of the Annapolis Accords criteria does not 
mean the study lacked scientific merit, but does reduce its appropriateness for deriving a pTI (Table 1). 
Table 2. Summarization of In vivo studies investigating the toxicity and health effects of intravenous 
silver nanoparticle exposure. 
Species 
(strain, 
sex) 
AgNP Treatment 
Dosea 
Exposure/Durat
ion 
Toxicological 
Health Effect 
Point of Departurea Appropriat
e-ness of 
Study for 
pTI 
Derivationb 
Reference 
Mouse studies 
Mouse 
(C57BL
6, wild 
type 
(WT) 
and 8-
oxo-
guanine 
DNA 
gly-
cosylas
e 
knocko
ut (KO) 
male) 
5 mg/kg bw/day 
(20 and 200 nm 
AgNP dispersed 
in dH2O/10X 
BSA/10X PBS in 
8:1:1 ratio) 
n = 6 per 
treatment 
Single injection 
and euthanized 
1 and 6 days 
after treatment 
Genotoxicity: ↑ 
DNA-SB and alkali 
sites in KO lung 
(200 nm, 7 days). 
↑ Fpg-ss lesions in 
lung (200 nm, 7 
days) and testis of 
WT (20 and 
200 nm, 7 days) 
Gene expression: 
↑ Atm, Rad51, 
Sod1, Fos and 
Mmp3 in KO lung 
(200 nm, 1 and 7 
days). ↑ Atr and 
Rad51 in KO testis 
(20 and 200 nm, 7 
days). 
NOAEL/LOAEL: None Lacks 
Power 
Asare 
et al., 
2016 
Mouse 
(CD-1, 
female) 
0.66 mg/kg bw/d
ay (10 nm AgNP 
in CT buffer) 
n = 8–10 
pregnant females 
per treatment 
3 daily injections 
of 2.2 mg/ml on 
GDs 7, 8, 9 and 
euthanized 1 
day after 
treatment 
Histopath: No 
abnormalities 
Reprod: ↑ number 
of smaller-sized 
GD10 embryos 
NOAEL/LOAEL: None Lacks 
Power, 
Corroborati
on and 
Universality 
Austin 
et al., 
2016 
Mouse 
(CD-1, 
female) 
1.2 and 
2.2 mg/kg bw/da
y (50 nm AgNP in 
CT buffer) 
n = 6–12 
pregnant females 
per treatment 
3 day 
treatments on 
GDs 7, 8, 9 and 
euthanized 1 
day after 
treatment 
Histopath: No 
abnormalities 
Reprod: No gross 
abnormalities to 
embryo 
NOAEL: 
2.2 mg/kg bw/day 
No adverse 
effectb 
Austin 
et al., 
2012 
Mouse 
(Balb/c, 
unknow
n 
gender) 
0.2, 2 and 
5 mg/kg bw/day 
(20 nm AgNP 
maintained in 4% 
polyoxy-ethylene 
glycerol trioleate 
Single injection 
and euthanized 
8 h after 
treatment 
Toxicity: No effect 
on body weight 
Hepatic: ↑ ER 
stress marker 
levels 
(5 mg/kg bw/day) 
NOAEL: 
2 mg/kg bw/day 
Lacks 
Power and 
Universality 
Chen 
et al., 
2016 
Species 
(strain, 
sex) 
AgNP Treatment 
Dosea 
Exposure/Durat
ion 
Toxicological 
Health Effect 
Point of Departurea Appropriat
e-ness of 
Study for 
pTI 
Derivationb 
Reference 
and 4% Tween 
20) 
n = 3 per 
treatment 
Blood: ↓ 
lymphocyte 
percentage and ↑ 
IL-6 
Histopath: 
Thickened alveolar 
walls, multifocal 
consolidation and 
infiltration of focal 
inflammatory cells 
in lungs. 
Disorganized 
hepatic cords, 
damaged hepatic 
lobules, edema 
cytoplasm and 
ballooning-like 
tissue changes in 
the liver. No 
effects in the brain, 
heart, spleen and 
kidneys. ↑ 
apoptotic cells in 
the lung, liver, 
spleen and kidneys 
(5 mg/kg bw/day). 
Mouse 
(Balb/c, 
female) 
0.25 mg/kg bw/d
ay (10, 75 and 
110 nm AgNP in 
5% isotonic 
glucose solution) 
n = 3 per 
treatment 
Single injection 
and euthanized 
4 h or 1, 3, 7 
days after 
treatment. 
3 injections on 
days 1, 4 and 10 
and euthanized 
7 days later 
Toxicity: Liver, 
kidney and lung 
had inflammation 
(greatest after 75 
or 100 nm) 
NOAEL/LOAEL: None Lacks 
Power and 
Universality 
Guo et al., 
2016 
Mouse 
(CD-1, 
male) 
1.0 mg/kg bw/da
y (14 nm, citrate-
coated AgNP) in 
Injections on 0, 
3, 6, 9, and 12 
days and 
Toxicity: No effect 
on body weight 
Histopath: ↑ 
NOAEL/LOAEL: None Lacks 
Power 
Garcia 
et al., 
2014 
Species 
(strain, 
sex) 
AgNP Treatment 
Dosea 
Exposure/Durat
ion 
Toxicological 
Health Effect 
Point of Departurea Appropriat
e-ness of 
Study for 
pTI 
Derivationb 
Reference 
PBS 
n = 6 per 
treatment 
euthanized 15, 
60, and 120 
days 
lumen volume and 
tubule diameter 
and ↓ 
seminiferous 
epithelium volume 
density in the testis 
(15 and 60 days). 
↑ % of apoptotic 
germ cells in the 
testis. ↑ cytoplasm 
and size of Leydig 
cells in the testis 
(15 and 60 days). 
Hormone: No 
effect in serum 
levels of LH or FSH. 
↑ serum and 
intratesticular 
testosterone at 15 
days 
Reprod: No effects 
on sperm 
concentration and 
motility (15–20 
days) 
Mouse 
(B6C3F
1, 
male) 
0.5, 1.0, 2.5, 10, 
20 mg/kg bw/day 
(5 nm, PVP-
coated AgNP) 
25 mg/kg bw/day 
(15–100 nm, 
PVP-coated 
AgNP) 
25 mg/kg bw/day 
(10–80 nm, 
silicon-coated 
AgNP) 
n = 5 per 
treatment 
Single injection 
(5 nm, PVP-
coated) 
Single injection 
and 3 day 
repeat dose 
(15–100 nm, 
PVP-coated and 
10–80 nm, 
silicon-coated) 
Gentox: 
Cytotoxicity of 
reticulocytes (PVP-
coated) and 
presence of 
oxidative damage 
(Comet Assay) in 
liver (PVP  and 
silicon-coated 
AgNPs). No 
increase in 
mutation 
frequencies in the 
Pig-a gene or the 
NOAEL (5 nm PVP-
coated): 
20 mg/kg bw/day 
Lacks 
Corroborati
on and 
Universality 
Li et al., 
2014 
Species 
(strain, 
sex) 
AgNP Treatment 
Dosea 
Exposure/Durat
ion 
Toxicological 
Health Effect 
Point of Departurea Appropriat
e-ness of 
Study for 
pTI 
Derivationb 
Reference 
percent of 
micronucleated 
(MN) reticulocytes. 
Mouse 
(CD-1, 
male) 
10 mg/kg bw/day 
(10, 40 and 
100 nm, CT- or 
PVP-coated, 
spherical AgNP 
suspended in 
Milli-Q water) 
n = 3 per 
treatment 
Single injection 
and euthanized 
1 day after 
treatment 
Toxicity: 2 
mortalities. ↓ 
body weight, ↑ 
spleen weight. 
Midzonal 
hepatocellular 
necrosis and gall 
bladder 
hemorrhage 
(10 nm). 
NOAEL/LOAEL: None Lacks 
Power and 
Corroborati
on 
Recordati 
et al., 
2016 
Mouse 
(ICR, 
male 
and 
female) 
7.5, 30, and 
120 mg/kg bw/da
y (15 nm AgNP 
suspended in 
saline) 
n = 5 per sex per 
treatment 
Single injection 
and euthanized 
at 6, 12 h and 1, 
7, 14 days 
Toxicity: No 
significant changes 
in body or relative 
organs weights 
were observed. 
Histopath: 
Infiltration of focal 
inflammatory cells 
and thickened 
alveolar walls in 
the lungs at day 7 
but diminished by 
day 14 
(120 mg/kg bw/day
). Liver edema and 
loose interstitial 
cytoplasm in 
hepatic cells 
(120 mg/kg bw/day
). None in brain, 
heart, spleen, 
kidneys, testicles 
or ovaries 
NOAEL:120 mg/kg bw
/day 
No adverse 
effectc 
Xue et al., 
2012 
Species 
(strain, 
sex) 
AgNP Treatment 
Dosea 
Exposure/Durat
ion 
Toxicological 
Health Effect 
Point of Departurea Appropriat
e-ness of 
Study for 
pTI 
Derivationb 
Reference 
Mouse 
(ICR, 
female) 
1.0 mg/kg bw/da
y (8 nm, spherical 
AgNP) 
n = 20 per 
treatment 
Single injection 
at 6.5 dpc and 
euthanized at 
13.5, 15.5 and 
17.5 dpc 
Reprod: ↑ 
progression of 
meiotic prophase I 
of female fetal 
germ cells 
Gene expression: 
↑ meiosis-specific 
genes, Stra8, Daz1, 
Scp1, Scp3 and 
Dmc1 and ↓ 
development-
related genes, 
Cx37, ZP 
glycoprotein 1, 2 
and 3, and Figla. ↑ 
imprinted genes, 
H19, Zac1, Ascl2, 
Snrpn, Kcnq1ot1, 
Peg3, Zac1, H19, 
Igf2r and Igf2. 
DNA methylation: 
↓ Zac1 and ↑ 
Igf2r 
NOAEL/LOAEL: None Lacks 
Power, 
Corroborati
on and 
Universality 
Zhang 
et al., 
2015a 
Rat Studies 
Rat 
(Wistar 
WU, 
male 
and 
female) 
0.0082, 0.0025, 
0.074, 0.22, 0.67, 
2.0 and 
6.0 mg/kg bw/da
y (20 and 100 nm 
AgNP suspended 
in PB) 
n = 2–4 per sex 
per treatment 
Daily injections 
for 28 days and 
euthanized 1 
day after final 
treatment 
Toxicity: ↓ thymus 
and ↑ spleen wt. 
Histopath: 
enlarged, brown-
colored spleen, 
liver, and lymph 
nodes 
Immunol: ↓ 
cytokine 
production 
including 
interferon-γ, IL-10, 
and IL-6, as well as 
increased serum 
BMDL05: 
0.14 mg/kg bw/day ↑ 
relative spleen weight 
and 
0.001 mg/kg bw/day 
for ↓ thymus weight 
Chosen as a 
critical 
study. Used 
to derive 
the pTI. 
De Jong 
et al., 
2013 
Species 
(strain, 
sex) 
AgNP Treatment 
Dosea 
Exposure/Durat
ion 
Toxicological 
Health Effect 
Point of Departurea Appropriat
e-ness of 
Study for 
pTI 
Derivationb 
Reference 
IgM, IgE and 
increased blood 
neutrophilic 
granulocytes 
Rat 
(Wistar, 
male) 
5 and 
10 mg/kg bw/day 
(20 nm, spherical 
AgNP in NaCl 
solution) 
5 mg/kg bw/day 
(200 nm; 
spherical AgNP in 
NaCl solution) 
n = 7 per 
treatment 
Single injection 
and euthanized 
1, 7 and 28 days 
after treatment 
At 
10 mg/kg bw/day 
(20 nm) 
significantly higher 
frequency of 
micronuclei after 4 
weeks (possible 
bone marrow 
toxicity) 
NOAEL:10 mg/kg bw/
day (20 nm) 
Lacks 
Power, 
Rigor, 
Corroborati
on and 
Universality 
Dobrzynsk
a et al., 
2014 
Rat 
(Spragu
e 
Dawley, 
male) 
10 mg/kg bw/day 
(117 nm AgNP 
dispersed in 
dH2O) 
n = 7 per 
treatment and 
n = 5 for controls 
Single injection 
and euthanized 
2 days after 
treatment 
Urine: Proteinuria 
Blood: ↑ 
creatinine and urea 
in serum 
Nephro: 
accumulation of 
glycosaminoglycan, 
hemorrhage in 
renal cortex and ↑ 
thickness of the 
parietal layer in 
Bowman's capsule. 
NOAEL/LOAEL: None Lacks 
Power, 
Corroborati
on and 
Universality 
Feng 
et al., 
2015 
Rat 
(Wistar 
Kyoto) 
0.238 mg/kg bw/
day (17.3 nm 
AgNP dispersed 
in H2O 
containing 4% 
each of PGT and 
Tween 20) 
n = 3 per 
treatment 
Single injection 
and euthanized 
1 day after 
treatment 
No changes in 
glutathione, ↑ in 
TNF-α, IL-1R1, and 
MIP-2 gene 
expression (24 h) 
NOAEL/LOAEL: None Lacks 
Power and 
subtle 
effects not 
considered 
critical 
Gaiser 
et al., 
2013 
Species 
(strain, 
sex) 
AgNP Treatment 
Dosea 
Exposure/Durat
ion 
Toxicological 
Health Effect 
Point of Departurea Appropriat
e-ness of 
Study for 
pTI 
Derivationb 
Reference 
Rat 
(Wistar, 
male) 
5 and 
10 mg/kg bw/day 
(20 nm, spherical 
AgNP dispersed 
in 0.9% NaCl 
solution) 
5 mg/kg bw/day 
(200 nm, 
spherical AgNP 
dispersed in 0.9% 
NaCl solution) 
n = 24 per 
treatment 
Single injection 
and euthanized 
1, 7 and 28 days 
after treatment 
20 nm:Reprod: ↓ 
sperm count 
(5 mg/kg bw/day; 1 
and 28 days) and 
germ count 
(5 mg/kg bw/day). 
DNA damage in 
germ cells (5 and 
10 mg/kg bw/day 
at 24 h). 
200 nm:Morpholog
ical changes in 
testes (5 mg/kg 
bw/day) 
NOAEL (200 nm): 
5.0 mg/kg bw/day 
Lacks 
Power 
Gromadzk
a-
Ostrawska 
et al., 
2012 
Rat 
(Wistar, 
male) 
4, 10, 20 and 
40 mg/kg bw/day 
AgNP 
(13 nm dispersed 
in ethylene 
glycol) 
n = 6 per 
treatment 
5 day intervals 
for 32 days and 
euthanized after 
treatment 
Toxicity: ↓ in body 
weight (20 and 
40 mg/kg bw/day 
after 15 d 
exposure). No 
effect in organ 
weight. 
Hematol: ↓ 
platelet counts and 
↑ white blood 
cells (20 and 
40 mg/kg bw/day) 
Hepatotox: ↑ ALT 
and AST (20 and 
40 mg/kg bw/day) 
and ↑ ALP and 
GGTP 
(40 mg/kg bw/day)
. 
Blood: ↑ ROS and 
DNA damage. 
Histopath: No 
inflammation, 
damage or 
morphological 
NOAEL: 
10 mg/kg bw/day 
Lacks 
Power 
Tiwari 
et al., 
2011 
Species 
(strain, 
sex) 
AgNP Treatment 
Dosea 
Exposure/Durat
ion 
Toxicological 
Health Effect 
Point of Departurea Appropriat
e-ness of 
Study for 
pTI 
Derivationb 
Reference 
changes in the liver 
or kidney. 
Rat 
(Wistar 
WU, 
male) 
0.0082, 0.0025, 
0.074, 0.22, 0.67, 
2.0 and 
6.0 mg/kg bw/da
y AgNP 
(20 nm,CT-coated 
dispersed in CT) 
n = 5 per 
treatment 
Daily injections 
for 28 days and 
euthanized 21 
days after 
treatment 
Toxicity: ↓ body 
and thymus weight 
and ↑ spleen 
weight and cell 
number. 
Immunol: ↑ spleen 
monocytes and ↓ 
KLH-specific IgG 
BMD (BMDL05): 
0.98 (0.76) 
mg/kg bw/day ↑ 
spleen wt. 
1.3 (0.76) 
mg/kg bw/day 
↓ thymus wt. 
Chosen as a 
critical 
study but 
was not 
used to 
derive the 
pTI. 
Vandebrie
l et al., 
2014 
Rat 
(Spragu
e 
Dawley, 
male) 
5, 10 and 
45 mg/kg bw/day 
AgNP (7.2 nm, 
spherical) in H2O 
n = 6 per 
treatment and 12 
per control 
Single injection 
or daily for 3 
days 
Toxicity: ↓ body 
weight 
Neurotox/Behavior
al: Locomotor 
activity appeared 
to be sensitive and 
rearing freq. ↓ 
(45 mg/kg bw/day) 
LOAEL: 
45 mg/kg bw/day 
Lacks 
Power, 
Corroborati
on and 
Universality 
Zhang 
et al., 
2013 
Rabbit Studies 
Rabbit 
(SPF 
New 
Zealand 
White, 
male) 
0.6 mg/kg bw/da
y AgNP (45 nm in 
dH2O and PVP 
(<1%)) 
n = 8 per 
treatment 
Single injection 
with 
one euthanized 
from each group 
at 21, 42, 84 and 
105 days and all 
euthanized at 
126 days 
Toxicity: No effect 
on body weight 
Histopath: No 
effect in testes 
Reprod: Lower % 
of motile, vigor and 
oxygen 
consumption of 
sperm cells. Sperm 
had acrosome and 
mitochondrial 
damage. 
NOAEL/LOAEL: None Lacks 
Power 
Castellini 
et al., 
2014 
Rabbit 
(SPF 
New 
Zealand 
White, 
male) 
0.5 and 
5.0 mg/kg bw/da
y AgNP (7.9 nm, 
citrate-coated in 
isotonic 5% 
glucose solution) 
Single injection 
with 
tissue sampling 
at 1, 7 and 28 
days 
Histopath: 
Pigmentation in 
liver, increased 
inflammatory cell 
infiltration levels in 
liver, lung and 
LOAEL: 
5.0 mg/kg bw/day 
Lacks 
Power 
Lee et al., 
2013 
Species 
(strain, 
sex) 
AgNP Treatment 
Dosea 
Exposure/Durat
ion 
Toxicological 
Health Effect 
Point of Departurea Appropriat
e-ness of 
Study for 
pTI 
Derivationb 
Reference 
n = 4 per 
treatment 
kidneys 
(5.0 mg/kg bw/day
) 
↑: increased; ↓: decreased; ALP: alkaline phosphatase; ALT: alanine transaminase; AST: aspartate 
aminotransferase; Atm: Ataxia telangiectasia mutated; BMD: bench-mark dose; BMDL05: BMD 95% 
lower confidence limit; BSA: bovine serum albumin; CT: citrate; dH2O: distilled water; Ddb2: damage 
specific DNA binding protein 2; dpc: days post conception; DNA-SB: DNA strand breaks; ER: 
endoplasmic reticulum; Fpg-ss: Formamidopyrimidine DNA glycosylase sensitive sites; GD: gestational 
day; KO: 8-oxoguanine DNA glycosylase knock-out; LOAEL: lowest-observed-adverse-effect-level; 
Mmp3: matrix metallopeptidase 3; n: sample size; NaCl: sodium chloride; NOAEL: no-observed-
adverse-effect level; PB: phosphate buffer; PBS: phosphate buffered saline; PGT: polyoxyethylene 
glycerol trioleate; PVP: polyvinylpyrrolidone; ROS: reactive oxygen species; Sod1: superoxide 
dismutase 1. 
amg/kg bw/day. 
bBased on the Annapolis Accords principles (Gray et al., 2008). 
cStudy has no adverse effect so can be excluded from further evaluation by the Annapolis Accords principles. 
2.3. Identification of the point-of-departure (POD) 
Two i. v. 28-day repeated AgNP dose toxicity studies in rats by De Jong et al. (2013) and Vandebriel 
et al. (2014) were deemed appropriate key studies for derivation of the pTI value for AgNPs released 
from blood-contacting medical devices (Table 2 and Supplemental Material). De Jong et al. (2013) 
(Table 3) and Vandebriel et al. (2014) met the principles outlined in the Annapolis Accords (Gray et al., 
2008) (Table 1). The ToxRTool was used to further verify the study quality and reliability of data of 
these two studies, and both were assigned a category of reliable with restrictions (score of 2) confirming 
their appropriateness for derivation of the pTI. Both studies were of similar experimental design with 
minor differences as Vandebriel et al. (2014) was a follow-up study to De Jong et al. (2013). The study 
by De Jong et al. (2013) analyzed the toxic effects of repeated 28-day dosing of 20 and 100 nm AgNP 
with no recovery period prior to evaluating critical health effects. Vandebriel et al. (2014) analyzed the 
toxic effects of repeated 28-day dosing of 20 nm, citrate-coated AgNPs for 28 days with a 28-day 
recovery period prior to evaluating critical health effects (Table 2). Both studies report BMDL05, the 
lower limit of the 95% confidence interval surrounding the BMD, for multiple toxicological parameters 
including body, spleen, thymus and liver weight, blood chemistry, hematology parameters and immune 
parameters. The BMDL05 was determined from fitting a dose-response curve to the dataset over the 
entire dose range studied (De Jong et al., 2013, Vandebriel et al., 2014). 
Table 3. In vivo Critical Study (De Jong et al., 2013) Chosen to Derive the Provisional Tolerable Intake 
Value for Intravenous Silver Nanoparticle Exposure Met the Annapolis Accords Criteria. 
Principle Criteria for Inclusion in Derivation of a Tolerable Intake Value 
Rigor 
The selected study properly conducted methods and reporting during their analysis of AgNP 
toxicity leading to increased confidence: 
− Followed OECD Guideline 407, for the testing of chemicals 
− Used a wide dose range (0, 0.0082, 0.0025, 0.074, 0.22, 0.67, 2.0, 6.0 mg/kg bw/day) as 
opposed to the conventional three dose group exposure design (low, mid and high dose) 
− Treated with repeated dose exposures as opposed to a single injection 
− Use of two different sizes of AgNPs (20 and 100 nm) 
− Incorporated both male and female animals 
− Provided toxicity data on general (e.g. body and target organ weight change) as well as specific 
(immunological) endpoints 
− Measured levels of biochemical parameters in blood serum 
− Provided histopathological analysis of targeted organs including spleen, thymus, liver, and 
lymph nodes 
Power 
Statistical power of the study was appropriate to have the ability to detect effects of a given 
magnitude including: 
− Sample size per treatment was small, but the increase in the number of dose groups improved 
the characterization of the dose response. 
− Provided a robust and adequately conducted statistical analysis for the calculation of the 
BMD05 for several parameters 
Corroboration Similar effects in immunologically functional tissues were reported in multiple studiesa,b. 
Universality Similar effects are reported in different speciesa. 
Proximity Critical health effects shown in a species taxonomically related to humans such as rodentsa,b. 
Relevance Toxic response in animal models include metabolism, mechanisms of damage and repair, and molecular targets of toxic action is expected to be the same in humans. 
Cohesion A similar plausible biological explanation is seen across studiesb. 
aRecordati et al., 2016. 
bVandebriel et al., 2014. 
The most sensitive critical health effect reported in the critical study is selected as the POD for 
derivation of a pTI value. When multiple critical health effects are reported in the critical study, or 
between multiple studies, selection of the POD is based on the lowest POD reported, with the highest 
magnitude of response (e.g. percent change or change in standard deviation from the control). The use of 
a NOAEL has limitations due to its determination being based on one experimental dose tested, 
dependence on doses and dose spacing chosen by the study authors, and the sample size of the animals 
per each dose group (Filipsson and Victorin, 2003). More advanced procedures such as benchmark dose 
(BMD) analysis can identify a POD value by including dose response data from the entire study, based 
on selection of the response level by the investigator (Weldon et al., 2016, EFSA Scientific Committee, 
2012, FDA, 2001, Crump, 1984) reducing the variability of the POD to ≤10% from a possible ≥20% 
when using a NOAEL (Gaylor and Kodell, 2000). The BMD includes calculation of the variability in the 
dose–response data as the 90 or 95% confidence limit of the BMD is calculated and presented as the 
BMDL10 or BMDL05, respectively (Weldon et al., 2016). 
We applied this critical effect selection concept to De Jong et al. (2013) and Vandebriel et al. (2014). 
The critical health effects reported from exposure to 20 nm AgNP by De Jong et al. (2013) was an 
increase in spleen weight, BMDL05 of 0.14 mg/kg bw/day (maximal response of +150%) and a decrease 
in thymus weight, BMDL05 of 0.001 mg/kg bw/day (maximal response of −17.4%). Vandebriel et al. 
(2014) confirmed these findings reporting an increase in spleen weight and a decrease in thymus weight 
with a BMDL05 of 0.76 mg/kg bw/day for both endpoints. The BMDL05 of 0.14 mg/kg bw/day for 
increased spleen weight reported in De Jong et al. (2013) qualified to serve as the critical study for 
derivation of the pTI based on the BMDL05 being the lowest critical health effect with the highest 
response. The increased BMDL05 values reported in Vandebriel et al. (2014) may have been due to the 
28-day recovery period after the final treatment used in the study; whereas, De Jong et al. (2013) did not 
have a recovery period. 
3. Derivation of a provisional tolerable intake 
3.1. Evaluation of uncertainties 
The uncertainty factor (UF) concept is integral to safety assessment to ensure when extrapolating the 
POD derived in animal models to human health that the value yields a no-adverse-effect dose for the 
greater majority of the human population including sensitive subpopulations (Dankovic et al., 2015). 
UFs considered are interindividual variability among the human population (UF1), interspecies 
variability in response to exposure when extrapolating data from animal models to humans (UF2) and 
lack of chronic toxicity exposure data (UF3) (FDA, 2001). Use of a default of 10 for each UF employed 
is standard when data is lacking; however, UFs should be derived on a case-by-case basis ranging from 
1 to 10 based on chemical-biological specific adjustment factors when available or with scientific-
support based on data in literature (EFSA Scientific Committee, 2012, Dankovic et al., 2015). The 
rationale for assigning uncertainty factors (UF) in the derivation of the provisional pTI in our study was 
in accordance to guidelines from the International Organization for Standardization (ANSI/AAMI/ISO 
10993–17:2002/(R)2012, 2003). 
3.1.1. Interindividual variability in human population (UF1) 
An UF1 accounts for interindividual variability among the human population. When data assessing 
human variation is lacking, a default of 10 is typically assigned to account for the range of human 
variability when the safety assessment has been based on animal studies (ANSI/AAMI/ISO 10993-
17:2002/(R)2012, 2003). If animal studies suggest that variation among humans may be significant, an 
UF1 of or approaching 10 is selected (ANSI/AAMI/ISO 10993-17:2002/(R)2012, 2003). Sex-related 
differences were found in a mouse study reporting a significant difference in the elimination of Ag from 
blood during the 24 h after i. v. AgNP (15 nm) treatment, with a half-life of 29.9 h in females compared 
to 15.6 h in males. Additionally, the lungs and kidneys showed a sex-dependent accumulation of Ag 
with higher concentrations in females compared to males (Xue et al., 2012) (Table 4). Other exposure 
routes have also found sex-related differences after AgNP exposure. A 28-day oral toxicity study in rats 
reported a 2-fold increase in AgNP in female kidneys compared to males with higher accumulation 
found in all kidney regions including the cortex, medulla, inner medulla and cortical glomeruli 
compared to males (Kim et al., 2008, Kim et al., 2009). A 90-day inhalation study in rats found 
statistically significant increases (p < 0.01–0.05) in parameters of lung inflammation in females 
compared to males (Sung et al., 2008). Additionally, interindividual differences in the excretion of Ag in 
urine and feces between rats have been reported after exposure with 20 and 200 nm AgNP 
(Dziendzikowska et al., 2012). These animal model studies suggest that sex-related and interindividual 
differences in AgNP toxicokinetics may exist in humans. Due to the lack of i. v. studies characterizing 
individual variability in humans and animal model data indicating the potential for interindividual 
variability between sexes, a default UF1 of 10 was assigned. 
Table 4. Pharmacokinetic or Biodistribution Studies of Intravenous Exposure to 20 ± 5 nm Silver 
Nanoparticles. 
Species 
(strain, 
sex) 
AgNP Treatmenta Duration Tissue Distribution and 
Excretionb 
Half-
life 
Reference 
Mouse 
(BALB/c, 
male and 
female) 
1.3 mg/kg bw/day (25 nm, 
PVP-coated AgNP spheres 
suspended in PBS) 
Injected 2x a week for 28 
days 
n = 3–5 per treatment 
15, 39 and 
78 days 
(females) 
120 days 
(males) 
Sp > Li > Ki » Lu > H 
(females, levels ↓ over time) 
Te > Sp > Li » Ki > H > Ln > M (120 
days) 
NR Wang et al., 
2013 
Mouse 
(ICR, male 
and 
female) 
120 mg/kg bw/day (15 nm 
AgNP dispersed in saline) 
Single injection 
n = 6 per sex per treatment 
10, 20, 
30 min; 1, 3, 
6, 12 h; 1, 7, 
14 days 
Sp > Li > Lu > Ki (females had 
higher silver levels in the Lu and 
Ki than males) 
NR Xue et al., 2012 
Rat 
(Wistar, 
male) 
5 mg/kg bw/day (20 nm, 
spherical AgNP dispersed in 
NaCl solution) 
Single injection 
n = 8 per treatment 
1, 7, 28 days Li » Sp > Ki > Lu > Br (1 day) 
Lu > Li > Sp > Ki > Br (7 days) 
Ki » Li > Sp > Lu > Br (28 days) 
NR Dziendzikowska 
et al., 2012 
Rat 
(Wistar, 
male) 
0.0238–
0.0276 mg/kg bw/day 
(20 nm, spherical AgNP 
dispersed in PB) 
Single injection and 5-day 
repeat treatment 
n = 3 per treatment 
2, 3, 5, 6, 8, 
11 and 17 
day 
Li » Ki > Te > Sp > Lu > Br > H 
(single injection; Day 2) 
Li » Ki > Te > Sp > Lu > Br > H 
(5-day repeat treatment; Day 6) 
Li » Ki > Sp > Te > Br > Lu, H (5-
day repeat treatment; Day 17) 
NRc Lankveld et al., 
2010 
NaCl: sodium chloride; NR: Not reported; PB: phosphate buffer; PBS: phosphate buffered saline; PVP: 
polyvinylpyrrolidone. 
aSize (nm) and/or coating of particles, number of treatments and concentration (mg/kg bw/day). 
bBr, brain; Fe, feces; H, heart; K, kidneys; Li, liver; Ln, lungs; M, muscle; Se, serum; Sp, spleen; Te, testis; Th, 
thymus; Ur, urine. 
cAccumulation of AgNP occurred in all organs with most in kidneys (factor 5.5), liver (factor 5) and brain (factor 
4). 
3.1.2. Interspecies variability (UF2) 
UF2 accounts for uncertainty in extrapolating data from animal models to humans (ANSI/AAMI/ISO 
10993-17:2002/(R)2012, 2003). Traditionally, a default of 10 has been applied to account for inherent 
differences between animals and humans, who may be more sensitive to chemical critical health effects 
(Lehman and Fitzhugh, 1954). If the toxicity and toxicokinetics are known and similar between animals 
and humans, a smaller uncertainty factor may be used with justification (ANSI/AAMI/ISO 10993-
17:2002/(R)2012, 2003). There is currently limited data on the pharmacokinetics, pharmacodynamics 
and toxicity mechanisms of AgNP to evaluate the relevance of animal data for human responses (Lin 
et al., 2015, Sweeney et al., 2015, Bachler et al., 2013, Lankveld et al., 2010, Faustman, 1996). The 
pharmacokinetic and biodistribution studies available do not report the half-life of AgNPs after i. v. 
exposure to 20 ± 5 nm AgNPs (Table 4). Studies in smaller AgNPs by Park et al. (2011) and Lee et al. 
(2013) report the half-life of AgNPs (7.9 nm, citrate coated) is species-dependent with 4.1 days in rats 
and 11.7–16.3 days in rabbits, respectively, after injection. The half-life was approximately 3–4 fold 
higher in rabbits compared to rats. This increase in half-life for the larger mammal is consistent with a 
lower metabolic rate and longer circulation time allowing for development of a more stable NP protein 
corona before distribution to tissue or elimination from the body (Sahneh et al., 2015, Riviere, 2013). 
The NP protein corona is a collection of selectively adsorbed biomolecules as the NP comes into contact 
with complex biological fluids lowering surface energy, promoting dispersion and defining the 
biological interaction of the NP (Monopoli et al., 2012). The formation of the protein corona decreases 
the extracellular dissolution of AgNPs into ionic Ag leading to the cellular uptake of the particles 
(Shannahan et al., 2015). Additionally, the binding of opsonins could induce a rapid clearance of NP 
from the vascular system or the binding of a polyethyleneglycol coating can decrease the uptake by 
macrophage cells (Pozzi et al., 2014). 
Additionally, studies indicate that human male germ cells exhibit a lower capacity to repair some types 
of DNA oxidative lesions including 8-oxo-7,8-dihydroguanine (although 8-oxoguanine-DNA 
glycosylase-1 (hOGG1) was present) and showed poor removal of formamidopyrimidine-DNA 
glycosylase (Fpg)-sensitive lesions in general, which was not seen in rat male germ cells (Olsen et al., 
2003). Asare et al. (2016) reported that injection of 5 mg/kg bw/day 200 nm AgNPs into hOGG1 
knockout mice (proposed as an appropriate model for humans) induced DNA single stranded breaks, 
oxidative DNA lesions including Fpg-sensitive lesions and key DNA damage response and repair genes, 
Atm, Rad51, Sod1, Fos and Mmp3, in the lung and testis. 
These interspecies differences potentially cause extrapolation from animal models to humans to be 
difficult (Sahneh et al., 2015). An UF2 was assigned a 10 to account for the interspecies differences 
between rodents and humans after exposure to AgNPs. 
3.1.3. Route-to-route extrapolation (UF3) 
A UF3 accounts for the quality and relevance of the study data and can range from 1 to 100 considering 
but not limited to the study having only LOAEL data instead of NOAEL or BMD data; absence of 
supporting studies; inappropriate route of exposure; and lack of chronic study data (ANSI/AAMI/ISO 
10993-17:2002/(R)2012, 2003). In our literature review, no chronic studies were found for i. v. exposure 
to AgNP. A TI that is protective of critical health effects resulting from chronic exposure should be 
based on long-term repeated dosing (30–90 days) or a chronic dosing study (90 days–2 years) (U.S. 
EPA, 1996, OECD, 1995). A value of 3–10 is typically assigned to account for the possibility of 
identifying a lower POD for chronic toxicity when extrapolating from a subchronic animal study. 
Assessing the appropriate value is commonly determined by evaluating if the critical effect that is the 
basis of the POD could be expected to increase in incidence, severity or occur at a lower dose given 
longer exposure time (Dankovic et al., 2015). Following i. v. injection, one of the primary sites of 20 nm 
AgNP accumulation has been consistently demonstrated to be in the spleen (Table 4). The localization 
of particles within the spleen can be accounted for by their uptake by the abundant number of resident 
macrophage populations (Lankveld et al., 2010). The marginal zone and red pulp macrophages are the 
major particle scavengers in the spleen followed by the peritoneal macrophages and dendritic cells 
(Recordati et al., 2016, Xue et al., 2012). Phagocytosis of AgNPs stimulates inflammatory signals 
through the generation of reactive oxygen species in macrophage cells (Martinez-Gutierrez et al., 2012, 
Park et al., 2010a, Park et al., 2011). In vitro studies indicate AgNP induces oxidative stress resulting in 
endoplasmic reticulum stress (Chen et al., 2016) and apoptosis in spleen cells (Xue et al., 2012, 
Lankveld et al., 2010). 
Additionally, De Jong et al. (2013) examined the organ weight and histology of the testes and brain, 
which have been shown to be sensitive health effect endpoints, but reported no effects. AgNPs can cross 
the blood-testis and blood-brain barrier accumulating over time in these organs (Zhang et al., 2015a, 
Wang et al., 2013, Lee et al., 2013, Dziendzikowska et al., 2012, van der Zande et al., 2012, Lankveld 
et al., 2010, Sharma et al., 2010, Kim et al., 2009). In vivo i. v. studies in multiple species report testes 
toxicity after short-term AgNP treatment (Table 2) (Asare et al., 2016, Gromadzka-Ostrowska et al., 
2012, Castellini et al., 2014). AgNP-induced toxicity in on the male reproductive system and 
spermatozoa was seen after other routes of exposure (Lafuente et al., 2016, Zhang et al., 2015a, Sleiman 
et al., 2013, Miresmaeili et al., 2013, Kim et al., 2009). Adverse effects induced by AgNPs in the brain 
has been reported including neurotoxicity (Bagheri-Abassi et al., 2015, Shanker Sharma and Sharma, 
2012, Sharma et al., 2010, Tang et al., 2009). To account for the possibility that the critical study might 
have not examined the most sensitive health effect endpoint, a UF3 of 10 was assigned. 
3.2. Calculation of the tolerable intake 
A modifying factor (MF) of 1,000, which is the mathematical product of the three UFs 
(UF1·UF2·UF3 = MF), was applied to account for uncertainties including intraspecies variability 
(UF1 = 10), interspecies differences (UF2 = 10) and lack of chronic toxicity data (UF3 = 10). The pTI for 
long-term i. v. exposure to 20 nm, uncoated AgNPs was determined to be 0.14 μg/kg bw/day derived 
from the POD of 0.14 mg/kg bw/day for immunotoxicological effects as calculated below: 
4. Discussion 
In this safety assessment, a pTI value was derived for i. v. exposure to 20 nm AgNP. The critical health 
effect study appropriate for deriving the pTI was determined to be an i. v. 28-day repeated-dose toxicity 
study in rats performed by De Jong et al. (2013) who investigated the immunotoxicological effects of 
AgNP. The POD was based on the critical health effect of increased relative spleen weight in rats with a 
BMDL05 of 0.14 mg/kg bw/day. Histological analysis of the spleen revealed inflammation and a 
brownish pigment in the red pulp indicative of red blood cell degradation, as well as, a decrease in NK 
lymphocyte activity, as notable immunotoxic effects (De Jong et al., 2013). T, B and NK cell 
populations were increased in the spleen after treatment with 20 nm AgNP, and the authors suggest this 
increase in cell number may be responsible for the increase in spleen weight (De Jong et al., 2013). Such 
effects may be in part due to the preferential accumulation of AgNP in the spleen. In vitro studies 
investigating the toxicity of AgNP in spleen cells report AgNP induces oxidative stress of the 
endoplasmic reticulum (Chen et al., 2016) and apoptosis (Xue et al., 2012, Lankveld et al., 2010). 
Supporting studies report toxic effects in the testes and sperm, which are considered more sensitive 
health effects compared to increase in spleen weight because this effect occurs at lower treatment doses 
than what was reported in the critical study by De Jong et al. (2013). De Jong et al. (2013) found no 
changes in testes weight or histology after 6.0 mg/kg bw/day AgNP (20 nm) 28-day repeated i. v. 
exposure in rats. In contrast, Gromadzka-Ostrawska et al. (2012) reported decreased sperm and germ 
count and DNA damage in germ cells after i. v. exposure to 5 mg/kg bw/day AgNP (20 nm); however, 
Asare et al. (2016) reported a single i. v. injection of 5 mg/kg bw/day AgNPs (20 nm) did not 
significantly increase single strand breaks in the testis 7 days after treatment in mice (Table 2). Castellini 
et al. (2014) investigated the toxic effects of a single i. v. injection of 0.6 mg/kg bw AgNPs (45 nm) on 
the sperm quality of rabbits throughout a 126-day study reporting sperm cells with a lower percent of 
motility, vigor and oxygen consumption and acrosome and mitochondrial damage (Table 2). AgNPs 
were seen in the spermatids and ejaculated sperm; however, no effect was seen morphologically in the 
testes nor was libido, serum testosterone, sperm concentration or semen volume affected (Castellini 
et al., 2014). Although these supporting studies did not meet the Annapolis Accords criteria and not used 
to derive the pTI; the scientific merit of these studies were used in determining the level of uncertainty 
in deriving the pTI. 
Other routes of exposure, albeit at higher doses, collaborate with the observed toxic effects induced in 
the testes and sperm after i. v. AgNP exposure. Miresmaeili et al. (2013) reported oral gavage exposure 
to AgNP (70 nm) for 48 days induced a dose-dependent decrease in the number of primary 
spermatocytes, spermatids and spermatozoa with a NOAEL of 25 mg/kg bw/day and a LOAEL of 
50 mg/kg bw/day. Lafuente et al. (2016) investigated the subchronic toxic effects of polyvinyl 
pyrrolidone (PVP)-coated AgNPs (average particle core size of 25 nm) by oral gavage on epididymal 
sperm rat parameters and found sperm morphology abnormalities after 90 days of repeated dose 
treatment with 100 mg/kg bw/day PVP-AgNP. Based on the NOAEL (25 mg/kg bw day) and LOAEL 
(100 mg/kg bw/day) reported in Miresmaeili et al. (2013) and Lafuente et al. (2016), respectively, and a 
BAForal of 4% to account for oral bioavailability (Bachler et al., 2013, Loeschner et al., 2011, Kim et al., 
2010), the estimated i. v. NOAEL is calculated to be ranging from 1.0 to 4.0 mg/kg bw/day. Abdominal 
subcutaneous injection of AgNP (15 nm) in five doses over 13 days in mice induced reduction of the 
average testis weight (5 mg/kg bw/day; postnatal day PND42); reduction in the diameter of the 
convoluted tubules (1 and 5 mg/kg bw/day; PND28 and PND42); increase in the rate of abnormal sperm 
(5 mg/kg bw/day; PND42 and PND63) and decreased sperm concentration (5 mg/kg bw/day; PND100) 
(Zhang et al., 2015b). Furthermore AgNPs are known to accumulate in the testes (Wang et al., 2013, 
Lankveld et al., 2010) (Table 4). These testicular toxicity data observed at lower i. v. equivalent AgNP 
doses as compared to De Jong et al. (2013) suggests that immunotoxicity of the spleen may not be the 
most sensitive toxicological endpoint. To account for the uncertainty that the POD may have not been 
the most sensitive critical health effect, a default value of 10 was used for UF3. Use of default values for 
UF1, UF2, and UF3 results in a conservative MF of 1,000 to be applied to the POD pTI of 
0.14 μg/kg bw/day. This threshold dose represents acceptable exposure for non-cancer health effects 
resulting from particles leached from medical devices containing 20 nm, uncoated AgNP. 
At the time of writing this paper, no patient exposure studies are known investigating AgNPs 
released/leached from medical devices. Roe et al. (2008) examined the toxic risk of catheters coated 
with 3–18 nm AgNPs in vitro and in vivo. In vitro studies examined Ag release from radioactive Ag-
coated catheters (600 and 1000 μg/g) placed in saline solution over a period of 10 days. Ag released 
from the catheters was relatively constant with an average release of 45.1 ± 1.1 ng/cm for catheters 
coated with 1,000 μg/g Ag and 24.1 ± 2.4 ng/cm for catheters coated with 600 μg/g Ag. The release of 
Ag was higher on the first day than on the final day of the study, thereby resulting in a biphasic release 
of Ag over the time period. Biofilm inhibition and measurement of bactericidal activity was tested on 
600 μg Ag-coated catheters in growth medium for 24, 48 or 72 h. The catheters demonstrated significant 
antimicrobial activity against all tested microorganism inhibiting cell growth and biofilm formation for 
72 h. In vivo studies investigated the toxicity and biodistribution of Ag from radioactive Ag-coated 
catheters implanted in the dorsum of C57BI/6J mice and monitored for 10 days. Body weight decreased 
by 8% post treatment, but organ weight was unaffected. No other toxicity was reported. Ag excretion 
was higher in feces compared to urine with the highest fecal (4.50 ± 0.40 μg) amount on day 2 
(approximately 2.1% of implanted Ag) with a decline and plateau of Ag concentration in feces (0.6–
1.0 μg/day) by day 6. Silver urine excretion was low (0.02 μg/day) and accounted for 0.1% of the Ag 
implanted. Cumulative excretion of Ag in feces and urine over a 10 day period was 18.33 ± 0.99 μg and 
0.22 ± 0.04 μg. By day 10, approximately 84% of Ag remained attached to the catheters with an Ag 
recovery rate at 96% on average. The 4% of unaccounted for Ag was reported by authors to be at the 
implantation site or along the borders of the insertion pockets where the catheter was inserted (Roe 
et al., 2008). 
Using the AgNP catheter release information from Roe et al. (2008), a hypothetical patient exposure 
situation can be formulated. Assuming 25 μg AgNPs was released daily for 10 days (250 μg 
cumulative), this equates to 25% of AgNPs released from a catheter coated with 1,000 μg Ag/g of device 
weight. For a 70 kg patient (25 μg/day • 1 day/70 kg patient) (ANSI/AAMI/ISO 10993-
17:2002/(R)2012, 2003), the patient exposure per day from release of AgNPs from a catheter is 
calculated to be 0.357 μg/kg bw/day. The resulting hypothetical exposure value is 2 fold higher than our 
pTI of 0.14 μg/kg bw/day with a toxicological risk that is equivocal. 
Our pTI value for i. v. exposure to 20 nm AgNPs released from medical devices for i. v. applications can 
be compared to other risk assessment values. Weldon et al. (2016) derived an occupational exposure 
limit (OEL) of 0.19 μg/m3 for AgNPs from BMDs from subchronic rat inhalation toxicity assessments 
with the liver identified as the critical target organ. This OEL can be calculated for a 70 kg adult with an 
adult air consumption of 20 m3/day to be 0.05 μg/kg bw/day, which is 2.8 fold lower than the pTI 
calculated for long-term i. v. exposure to 20 nM AgNP. A Tolerable Daily Intake (TDI) value for oral 
exposure to AgNP based on noncancer effects was reported by Hadrup and Lam (2014) to be 
2.5 μg/kg bw/day. When a 4% value for oral bioavailability (4% BAForal) is taken into account, the 
health-based exposure limit equals to 0.1 μg/kg bw/day (Bachler et al., 2013, Loeschner et al., 2011, 
Kim et al., 2010). This TDI was based on a study by Park et al. (2010b) that reported a NOAEL of 
0.25 mg/kg bw/day in mice after daily oral exposure to AgNP (42 nm) for 28 days in both males and 
females and consideration of a UF of 100 based on Nielsen et al. (2008) (Hadrup and Lam, 2014). Our 
pTI for i. v. exposure to 20 nm AgNPs released from medical devices is similar to the calculated TDI for 
oral exposure accounting for 4% BAForal. 
5. Conclusion 
In summary, this safety assessment derived a pTI value for i. v. exposure to 20 nm AgNPs released from 
blood-contacting medical devices. Criteria for selecting relevant studies to determine a benchmark dose 
was based on the principles from the Annapolis Accords and ToxRTool analysis. The De Jong et al. 
(2013) study, a 28-day study in rats investigating a series of immunotoxicological endpoints after 
exposure to 20 nm AgNP, qualified to serve as the critical study for the pTI derivation. De Jong et al. 
(2013) reported the lowest dose-dependent critical health effect, which was a BMDL05 of 
0.14 mg/kg bw/day for increased spleen weight. To derive the pTI, a modifying factor (MF) of 1,000 
was applied to the POD to account for interindividual variability (10), potential interspecies difference 
in potency (10), and the lack of chronic toxicity study data (10) based on scientific review. 
The pTI for long-term i. v. exposure to 20 nm AgNPs is the first non-cancer risk assessment performed 
for the i. v. exposure of AgNP-containing medical devices. This pTI is not necessarily protective for 
other sizes or coatings of AgNPs or other administration routes of exposure. The pTI may be used to 
complete a safety assessment once data is available to estimate the dose of AgNP that patients are 
exposed to following release from blood-contacting medical devices. The approach will enable 
toxicological risk assessors to further develop a general index of acceptable toxicological risk with 
regard to patient i. v. exposure to AgNP released from medical devices as additional toxicological data 
becomes available. 
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